KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Fulgent Genetics (FLGT) over the last 11 years, with Q3 2025 value amounting to $48.6 million.

  • Fulgent Genetics' Cost of Revenue rose 797.16% to $48.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $185.4 million, marking a year-over-year increase of 465.16%. This contributed to the annual value of $176.3 million for FY2024, which is 460.17% down from last year.
  • Per Fulgent Genetics' latest filing, its Cost of Revenue stood at $48.6 million for Q3 2025, which was up 797.16% from $47.4 million recorded in Q2 2025.
  • Over the past 5 years, Fulgent Genetics' Cost of Revenue peaked at $77.7 million during Q1 2022, and registered a low of $35.9 million during Q2 2021.
  • In the last 5 years, Fulgent Genetics' Cost of Revenue had a median value of $47.3 million in 2023 and averaged $51.0 million.
  • In the last 5 years, Fulgent Genetics' Cost of Revenue skyrocketed by 172585.65% in 2021 and then tumbled by 3907.11% in 2023.
  • Over the past 5 years, Fulgent Genetics' Cost of Revenue (Quarter) stood at $62.1 million in 2021, then decreased by 11.94% to $54.7 million in 2022, then fell by 17.25% to $45.3 million in 2023, then decreased by 2.01% to $44.4 million in 2024, then rose by 9.45% to $48.6 million in 2025.
  • Its last three reported values are $48.6 million in Q3 2025, $47.4 million for Q2 2025, and $45.1 million during Q1 2025.